Related Experiment Video
Updated: Aug 14, 2025
Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
Published on: May 9, 2018
Human lung carcinomas synthesize immunoregulatory glucocorticoids
Verena M Merk1, Leonie Grob1, Achim Fleischmann2
1Chair of Biochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany.
Abstract:
The need for new options in lung cancer treatment inevitably leads back to basic research. The tumor itself and the tumor environment especially the interaction with the immune system need to be better understood to develop targeted therapies. In the context of lung cancer glucocorticoids (GC) are mainly known as a combination drug to attenuate side-effects of chemotherapies. However, endogenous extra-adrenal GC have been shown to substantially regulate local immune responses within various tissues, including the lung. In this study we investigated whether primary lung tumors have maintained the capacity to synthesize GC and may thereby regulate anti-tumor immune responses. We show that several non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC) cell lines express key steroidogenic enzymes and synthesize bioactive GC under steady state conditions. We also show that tumor-derived GC can inhibit splenic T cell activation, thus demonstrating their immunoregulatory potential. Moreover, steroidogenic enzymes were detected by quantitative RT-PCR and immunohistochemistry in tissue sections of different human lung tumors, further strengthening the idea that human lung carcinomas regulate their microenvironment by releasing immunoregulatory GC, which potentially contributes to immune evasion and treatment resistance.
Insights
Lung tumors can produce their own glucocorticoids (GC), which suppress anti-tumor immune responses. This discovery in non-small cell lung carcinoma and small cell lung carcinoma offers new avenues for targeted lung cancer therapies.
Area of Science:
- Oncology
- Immunology
- Endocrinology
Background:
- Targeted lung cancer therapies require deeper understanding of tumor-immune interactions.
- Glucocorticoids (GC) are known to mitigate chemotherapy side effects but also regulate local immune responses.
- Endogenous GC synthesis in lung tumors remains largely unexplored.
Purpose of the Study:
- To investigate if primary lung tumors synthesize GC.
- To determine if tumor-derived GC can modulate anti-tumor immune responses.
- To explore the role of GC in the lung tumor microenvironment and immune evasion.
Main Methods:
- Analysis of steroidogenic enzyme expression in lung cancer cell lines (NSCLC, SCLC).
- Detection of bioactive GC synthesis under steady-state conditions.
- Assessment of tumor-derived GC effects on splenic T cell activation.
- Quantitative RT-PCR and immunohistochemistry on human lung tumor tissues.
Main Results:
- Lung cancer cell lines express key steroidogenic enzymes and synthesize bioactive GC.
- Tumor-derived GC were shown to inhibit splenic T cell activation.
- Steroidogenic enzymes were detected in human lung tumor tissues, indicating local GC production.
Conclusions:
- Human lung carcinomas possess the capacity to synthesize immunoregulatory GC.
- Tumor-derived GC can inhibit anti-tumor immune responses, potentially contributing to immune evasion.
- Understanding this mechanism may lead to novel targeted lung cancer treatments.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
07:39The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018